Immunotherapy Approaches in Metastatic Melanoma

Melanoma is among the most immunogenic malignancies and, once metastatic, has historically faced poor prognosis. Over the past decade, immunotherapy has revolutionised treatment by harnessing the patient’s own immune system to target tumour cells. The cornerstone of this transformation is immune checkpoint blockade, targeting inhibitory receptors such as CTLA-4, PD-1 and PD-L1 to reinvigorate cytotoxic T-cell function. Combination strategies, pairing checkpoint inhibitors with radiotherapy, targeted small-molecule inhibitors or oncolytic viruses, have demonstrated synergistic antitumour activity while also uncovering challenges in resistance and toxicity. Adoptive cell therapies, including tumour-infiltrating lymphocyte expansion and engineered T-cell receptors, offer personalised approaches to bypass immune evasion. Biomarker development, notably assays for neoantigen burden and immune-related adverse events, is guiding patient selection and management. The tumour microenvironment, comprising stromal and immune-regulatory cells, remains a critical factor influencing response; modulation of this niche through cytokine therapies or myeloid cell targeting is under active investigation. Ongoing research is focusing on overcoming primary and acquired resistance, minimising off-target effects and optimising combination regimens. Together, these advances have extended survival in metastatic melanoma and established a template for immuno-oncology in other solid tumours globally.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Immunotherapy Approaches in Metastatic Melanoma publication trend

The graph below shows the total number of articles in immunotherapy approaches in metastatic melanoma across all publications each year (not limited to Nature Index journals).

Technical terms

Immune checkpoint inhibitors: Antibodies that block regulatory receptors (e.g., CTLA-4, PD-1) to enhance T-cell-mediated tumour killing.

Tumour microenvironment: The complex milieu of stromal cells, immune populations and signalling molecules surrounding a tumour.

Adoptive cell therapy: Infusion of ex vivo-expanded or genetically engineered T cells to target specific tumour antigens.

Oncolytic virus: A genetically modified virus that selectively infects and lyses tumour cells, augmenting immune activation.

Immune-related adverse events (irAEs): Autoimmune-like toxicities resulting from systemic immune activation by immunotherapy.

References

1. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Frontiers in Pharmacology (2018).
2. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. Journal of Immunology Research (2020).
3. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Frontiers in Medicine (2019).
4. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget (2018).
5. Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Frontiers in Oncology (2019).
6. The Influence of Tumor Microenvironment on Immune Escape of Melanoma. International Journal of Molecular Sciences (2020).